Patents by Inventor Tehila Ben Moshe
Tehila Ben Moshe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200277398Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.Type: ApplicationFiled: May 18, 2020Publication date: September 3, 2020Applicant: Famewave Ltd.Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
-
Publication number: 20200216557Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.Type: ApplicationFiled: December 2, 2019Publication date: July 9, 2020Applicant: Famewave Ltd.Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
-
Patent number: 10550196Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.Type: GrantFiled: April 27, 2015Date of Patent: February 4, 2020Assignee: Famewave Ltd.Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
-
Publication number: 20190256832Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: ApplicationFiled: March 18, 2019Publication date: August 22, 2019Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Tali Kizhner, Yoseph Shaaltiel
-
Patent number: 10280414Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: GrantFiled: June 29, 2017Date of Patent: May 7, 2019Assignee: Protalix Ltd.Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Tali Kizhner, Yoseph Shaaltiel
-
Patent number: 10081679Abstract: The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.Type: GrantFiled: November 25, 2014Date of Patent: September 25, 2018Assignee: CCAM BIOTHERAPEUTICS LTD.Inventors: Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Edna Meilin
-
Publication number: 20180148703Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: ApplicationFiled: June 29, 2017Publication date: May 31, 2018Applicant: Protalix Ltd.Inventors: Avidor SHULMAN, Ilya RUDERFER, Tehila BEN-MOSHE, Talia SHEKHTER, Yaniv AZULAY, Tali KIZHNER, Yoseph SHAALTIEL
-
Publication number: 20170355781Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.Type: ApplicationFiled: August 22, 2017Publication date: December 14, 2017Applicant: CCAM BIOTHERAPEUTICS LTD.Inventors: Gal MARKEL, Tehila BEN MOSHE, Yair SAPIR, Ilana MANDEL, Jacob SCHACHTER, Rona ORTENBERG
-
Patent number: 9771431Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.Type: GrantFiled: October 10, 2012Date of Patent: September 26, 2017Assignee: CCAM BIOTHERAPEUTICS LTD.Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
-
Patent number: 9708595Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: GrantFiled: November 10, 2015Date of Patent: July 18, 2017Assignee: Protalix Ltd.Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben Moshe, Talia Shekhter, Yaniv Azulay, Yoseph Shaaltiel, Tali Kizhner
-
Publication number: 20170166637Abstract: The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.Type: ApplicationFiled: November 25, 2014Publication date: June 15, 2017Applicant: CCAM BIOTHERAPEUTICS LTD.Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Edna MEILIN
-
Publication number: 20170044270Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.Type: ApplicationFiled: April 27, 2015Publication date: February 16, 2017Applicant: CCAM BIOTHERAPEUTICS LTD.Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Gal MARKEL, Jacob SCHACHTER, Rona ORTENBERG, Francis Joseph CARR, Robert George E. HOLGATE, Timothy David JONES
-
Publication number: 20160053247Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: ApplicationFiled: November 10, 2015Publication date: February 25, 2016Applicant: PROTALIX LTD.Inventors: Avidor SHULMAN, Ilya RUDERFER, Tehila BEN-MOSHE, Talia SHEKHTER, Yaniv AZULAY, Yoseph SHAALTIEL, Tali KIZHNER
-
Patent number: 9194011Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: GrantFiled: March 2, 2011Date of Patent: November 24, 2015Assignee: Protalix Ltd.Inventors: Avidor Shulman, Ilya Ruderfer, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay, Yoseph Shaaltiel, Tali Kizhner
-
Publication number: 20140271618Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.Type: ApplicationFiled: October 10, 2012Publication date: September 18, 2014Applicants: RAMOT AT TEL-AVIV UNIVERSITY LTD., CCAM BIOTHERAPEUTICS LTD.Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
-
Publication number: 20130017169Abstract: Multimeric protein structures are disclosed herein, as well a process for preparing same, and methods employing same for treating various diseases or disorders. The multimeric protein structures comprise at least two monomers of a therapeutic protein, including a TNF-alpha, a luteinizing hormone, an immunoglobin, a TNF-alpha receptor, a CTLA-4, a urate oxidase, a VEGF, a PDGF, a VEGF receptor, a PDGF receptor, an interleukin-17, and/or fragments thereof, the monomers being covalently linked to one another via a linking moiety. The multimeric protein structures exhibit improved performance as compared to the corresponding native proteins, including a longer lasting activity in vivo.Type: ApplicationFiled: March 2, 2011Publication date: January 17, 2013Applicant: PROTALIX LTD.Inventors: Ilya Ruderfer, Orit Shilovittzky, Avidor Shulman, Joseph Shaaltiel, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay
-
Publication number: 20120328592Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.Type: ApplicationFiled: March 2, 2011Publication date: December 27, 2012Applicant: Protalix Ltd.Inventors: Avidor Shulman, Llya Ruderfer, Tehila Ben-Moshe, Talia Sheckhter, Yaniv Azulay, Yoseph Shaaltiel, Tali Kizhner
-
Patent number: 8304384Abstract: The present invention relates to the regulatory role of caspase-8 in infection by intracellular pathogen, inflammation and wound healing.Type: GrantFiled: June 27, 2007Date of Patent: November 6, 2012Assignees: Yeda Research and Development Co., Ltd, Hadasit Medical Research Services and Development Ltd.Inventors: David Wallach, Rinat Abramovitch, Eitan Galun, Tehila Ben Moshe, Hila Barash
-
Publication number: 20120230974Abstract: A method of treating Fabry is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of alkaline alpha galactosidase, thereby treating Fabry disease.Type: ApplicationFiled: November 17, 2010Publication date: September 13, 2012Applicant: PROTALIX LTDInventors: Yoseph Shaaltiel, Tehila Ben-Moshe, Yaniv Azulay
-
Publication number: 20090269331Abstract: The present invention relates to the regulatory role of caspase-8 in infection by intracellular pathogen, inflammation and wound healingType: ApplicationFiled: June 27, 2007Publication date: October 29, 2009Applicants: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: David Wallach, Rinai Abramovitch, Eitan Galun, Tehila Ben Moshe, Hila Barash